NANJING, China, Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that the Company is seeking approval to manufacture and sell products containing zanamivir, one of only two WHO approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible.
GlaxoSmithKline granted a license to Simcere in 2006 to make products containing zanamivir. Simcere is the only pharmaceutical company in mainland China that has such a license.
"We look forward to obtaining the approval to manufacture and sell zanamivir in China. To this end, we have already begun to prepare the raw materials and manufacturing facilities required to launch this drug," commented Mr. Xiaojin Yin, Senior Vice President of Research and Development of Simcere Pharmaceutical Group.
No comments:
Post a Comment